Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
Sponsor
Fayoum University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06031337
Collaborator
(none)
46
1
2.9
15.7
Study Details
Study Description
Brief Summary
The study will include patients with oral cancer and healthy controls of both sexes. Subjects having any systemic diseases or other types of cancer will be excluded. All subjects will be selected from Oral Medicine Department, Faculty of Dentistry, Al Ahram Canadian University and Fayoum University. Informed consent will be obtained from all subjects enrolled in this study after explanation of the whole procedure.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational [Patient Registry]
Anticipated Enrollment
:
46 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
Anticipated Study Start Date
:
Sep 3, 2023
Anticipated Primary Completion Date
:
Nov 22, 2023
Anticipated Study Completion Date
:
Dec 1, 2023
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Oral Cancer Group 23 patients with oral cancer |
Diagnostic Test: ELISA
quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
|
| Control Group 23 age-and-sex-matched healthy individuals, as normal controls |
Diagnostic Test: ELISA
quantitative determination of salivary SOX7 using an Enzyme Linked Immunosorbent assay (ELISA) kit based on the sandwich principle according to the manufacturer's protocol.
|
Outcome Measures
Primary Outcome Measures
- salivary expression of SOX7 [2 months]
Eligibility Criteria
Criteria
Ages Eligible for Study:
12 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- patients with oral cancer
Exclusion Criteria:
- any systemic diseases or other types of cancer will be excluded
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fayoum University | Fayoum | Egypt |
Sponsors and Collaborators
- Fayoum University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Salsabeel,
Lecturer,
Fayoum University
ClinicalTrials.gov Identifier:
NCT06031337
Other Study ID Numbers:
- 1591985
First Posted:
Sep 11, 2023
Last Update Posted:
Sep 13, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: